Davita - Pocahontas is a medicare approved dialysis facility center in Pocahontas, Arkansas and it has 8 dialysis stations. It is located in Randolph county at 404 Camp Rd, Pocahontas, AR, 72455. You can reach out to the office of Davita - Pocahontas at (870) 248-0138. This dialysis clinic is managed and/or owned by Davita. Davita - Pocahontas has the following ownership type - Profit. It was first certified by medicare in June, 2016. The medicare id for this facility is 042595 and it accepts patients under medicare ESRD program.
| Name | Davita - Pocahontas |
|---|---|
| Location | 404 Camp Rd, Pocahontas, Arkansas |
| No. of Dialysis Stations | 8 |
| Medicare ID | 042595 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 404 Camp Rd, Pocahontas, Arkansas, 72455 | |
| (870) 248-0138 | |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
| NPI Number | 1891039210 |
| Organization Name | Ouachita Valley Dialysis |
| Doing Business As | Renal Treatment Centers Southeast Lp |
| Address | 1114 W Washington St Camden, Arkansas, 71701 |
| Phone Number | (615) 341-6376 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
| NPI Number | 1912399601 |
| Organization Name | Pocahontas Dialysis |
| Doing Business As | Ozark Dialysis Llc |
| Address | 404 Camp Rd Pocahontas, Arkansas, 72455 |
| Phone Number | (615) 341-6376 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
| NPI Number | 1871832832 |
| Organization Name | Iowa City Dialysis |
| Doing Business As | Northshore Dialysis Llc |
| Address | 2769 Heartland Dr Coralville, Iowa, 52241 |
| Phone Number | (615) 341-6376 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
| Dialysis patients with Hemoglobin data | 15 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 33 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 35 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 226 |
| Percentage of adult patients getting regular hemodialysis at the center | 94 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
| Adult patients getting regular peritoneal dialysis at the center | 10 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 67 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Davita - Pocahontas with elevated calcium levels.
| Patients with hypercalcemia | 44 |
| Hypercalcemia patient months | 310 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 50 |
| Patients with Serumphosphor less than 3.5 mg/dL | 5 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 15 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 40 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 24 |
| Patients with Serumphosphor greater than 7 mg/dL | 17 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 28 |
| Patient months included in arterial venous fistula and catheter summaries | 153 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 73 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 18 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 17 |
| Hospitalization Rate in facility | 122.8 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 615.1 |
| Hospitalization Rate: Lower Confidence Limit | 27.8 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago
The rate of readmission show you whether patients who were being treated regularly at Davita - Pocahontas were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 7.2 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 32.8 |
| Readmission Rate: Lower Confidence Limit | .3 |
News Archive
Nova Southeastern University researchers recently discovered that by testing the level of NER (nucleotide excision repair) gene expression, pediatric oncologists can determine the likelihood of early relapse (less than three years) in their acute lymphoblastic leukemia patients.
PET imaging has been shown to improve detection of a variety of cancers, and earlier tests have suggested this technique may be useful in identifying small tumors in patients with paraneoplastic neurological disorders. But PET imaging is not yet widely available, and clear indicators of clinically meaningful outcomes using PET are essential to warrant use with this patient population.
NovoStent Corporation, a privately held medical device company, today announced the 6-month follow-up results of the company's European clinical trial evaluating the use of its SAMBA Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease. The SAMBA Stent was designed to treat the highly varied presentation of atherosclerotic disease in the superficial femoral (SFA) and popliteal arteries by providing a unique combination of increased vessel coverage, strength and flexibility.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia, 41 percent of surveyed European hematologist-oncologists say that the favorable efficacy profile of Roche's MabThera (rituximab) is the most significant driver of their use of this brand, while 26 percent say MabThera's favorable risk-benefit profile is the most significant driver.
Juvenile Inflammatory Arthritis is a potentially debilitating childhood disease. Early detection and treatment of active arthritis may avert long term joint damage and disability.
› Verified 5 days ago